In the News

Outcomes of Poly-4-hydroxybutyrate Mesh in Ventral Hernia Repair: A Systematic Review and Pooled Analysis

Joseph A. Mellia, BA, Sammy Othman, BA, Hani I. Naga, BA, Charles A. Messa IV, BS, Omar Elfanagely, MD, Yasmeen M. Byrnes BA, Marten N. Basta, MD, John P. Fischer, MD, MPH*

Plastic Reconstructive Surgery Global Open 8(12):e3158.

Published online 16 December 2020

doi: 10.1097/GOX.0000000000003158

Link to Publicationhttps://pubmed.ncbi.nlm.nih.gov/33425570/

Abstract

Within the past decade, poly-4-hydroxybutyrate (P4HB) biosynthetic mesh has been introduced as a potential alternative to traditional biologic and synthetic mesh in ventral hernia repair (VHR). The aim of this study was to systematically assess clinical outcomes with the P4HB in VHR.

Methods: A literature search identified all articles published in 2000 involving the use of P4HB in VHR. Descriptive statistics were used to synthesize collective data points, including postoperative outcomes. A pooled analysis of postoperative outcomes was performed using chi-square test and Fisher exact test.

Results: Across 7 studies, the P4HB was used in 453 patients. The mean rate of surgical site infection (SSI) was 6.8% (31/453), reoperation 10.7% (30/281), and recurrence 9.1% (41/453). At an average follow-up of 26.8 months, the incidence of recurrence was 10.4% (28/270). Onlay was significantly associated with increased recurrence (14.2% versus 4.4%, P = 0.001). Among sublay placements, there was no difference in recurrence in clean (Center for Disease Control [CDC] 1) or contaminated (CDC >1) wounds (2.7% versus 6.1%, P = 0.585), but contaminated wounds were associated with increased SSI (2.7% versus 15.2%, P = 0.028). Ventral Hernia Working Group grade 2 and 3 did not have different incidences of recurrence (8.0% versus 5.1%, P = 0.526) nor SSI (5.1% versus 14.6%, P = 0.265).

Conclusions: Overall, clinical outcomes of the P4HB mesh in VHR are acceptable. The P4HB mesh serves as a reliable alternative to traditional synthetic and biologic mesh across a range of defect characteristics and patient health conditions. Further research is needed to better understand the conditions in which it may provide a clinical benefit over traditional mesh types.

DISCLOSURES

Authors and Funding: John P. Fischer has received payments as a consultant from Baxter, Becton-Dickinson, Gore, Integra Life Sciences and Tepha, Inc. This research did not receive financial support for the study. The other authors have no financial interest to declare.